Industry News

Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that it continues to remain on track to report topline data this quarter from its Phase 2 trials evaluating HS-410 and HS-110 for the treatment of non-muscle invasive bladder cancer and non-small cell lung cancer, respectively, as well as its Phase 1 b trial evaluating HS-110 in combination with Bristol-Myers..."/>
Heat Biologics Remains on Track to Achieve  Multiple Topline Data Readouts this Quarter
Tonix Pharmaceuticals Holding Corp., which is developing a next-generation treatment for posttraumatic stress disorder, announced today that it will present at the Second Annual Dawson James Securities Small Cap Growth Stock Conference being held October 20, 2016 in Jupiter, Florida.. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of Tonix’ s PTSD clinical program. Tonix recently..."/>
Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
Acorda Therapeutics, Inc. is developing CVT-301 for the treatment of OFF periods in people with Parkinson’ s disease. As PD progresses, people with Parkinson’ s experience OFF periods, which are characterized by the re-emergence of PD symptoms. These include motor symptoms such as impaired..."/>
Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Science Translational Medicine
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on facioscapulohumeral muscular dystrophy and the Company’ s Phase 2 clinical trial of ACE-083 in FSHD patients. The webinar will be led by neuromuscular..."/>
Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2016 financial results after the market close on Thursday, November 10, 2016. The company’ s management will discuss the results during a conference call and..."/>
Glaukos Corporation to Release Third Quarter 2016 Financial Results after Market Close on November 10
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, today announced that it will release third quarter 2016 financial results before the market opens on Thursday, October 27, 2016, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 877-930-8295 or 253-336-8738."/>
West to Host Third Quarter 2016 Conference Call
Immunomedics stated on Wednesday that it has raised gross proceeds of USD30m from its underwritten offering of common stock and warrants. The company closed the sale of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock for gross proceeds of USD30m. Each share of common stock and its accompanying warrant was priced at USD3.00, added the company."/>
Immunomedics announces USD30m from financing of common stock & warrants
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that it received a response from the U.S. Food and Drug Administration regarding the clinical hold of Aptose’ s Phase 1 b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose that the hold would not be..."/>
Aptose Provides Update on FDA Clinical Hold of APTO-253
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced its Chairman and CEO, Zami Aberman, has been re-elected as Member of the Board of Directors of the Alliance for Regenerative Medicine. Aberman’ s second year serving on the Board of the Washington, D.C.-based, international organization that represents the gene therapy, cell therapy and tissue engineering sector. Pluristem has been a member of ARM..."/>
Pluristem CEO Zami Aberman Re-Elected to Alliance for Regenerative Medicine’s Board of Directors
Inspyr Therapeutics, Inc., a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointment of Richard Buller, M.D., Ph.D. to its Board of Directors. “We are excited to have Rich join the Board as his extensive experience in the development of novel oncology therapeutics will very valuable as we plan for additional clinical studies for our lead oncology therapeutic Mipsagargin,” said Chris..."/>
Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors
RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill’ s Chief Executive Officer, will present at the BIO Investor Forum 2016, on Tuesday, October 18, 2016, at 10:30 am PDT, at the Westin St."/>
RedHill Biopharma to Present at the BIO Investor Forum 2016
TransEnterix, Inc., a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robot at the Clinical Congress 2016 of the American College of Surgeons. The congress will be held on October 16-20, 2016 in Washington, DC."/>
TransEnterix to Feature Senhance™ Surgical Robot at American College of Surgeons Clinical Congress
HMS Holdings Corp revealed on Wednesday the addition of Alex Michael Azar II to its board of directors with immediate effect. Currently, Azar serves as president, Lilly USA LLC, the largest affiliate of Eli Lilly& Company. Most recently, Azar was employed as the deputy secretary and general counsel at the US Department of Health& Human Services."/>
HMS Holdings Corp names Alex Michael Azar II to board
Insys Therapeutics, Inc. today announced that its preliminary estimated revenues from Subsys ® for the third quarter of 2016 will be in the range of $54 million to $55 million. The Company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth.. Estimated revenues for the quarter reflect a decline in prescriptions as the Company continues to believe that the..."/>
Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the Third Quarter 2016
Danaher Corp., the companies said. Terms of the deal were not disclosed. Analysts put the purchase price at around USD 700 m."/>
Purification Consumables Firm Phenomenex Agrees to Danaher Buyout
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, today announced the appointment of Suzette Jaskie as Vice President Global Medical Affairs. This Smart News Release features multimedia. View the full release here:"/>
Corindus Vascular Robotics Appoints Suzette Jaskie Vice President Global Medical Affairs
Triple-S Management Corporation, a leading managed care company in Puerto Rico, today announced the star ratings for its Medicare Advantage plans from the Centers of Medicare and Medicaid Services for payment year 2018. The purpose of this rating system is to provide Medicare beneficiaries with information to compare the quality of care across different plans. The company's HMO offering increased from 3 to 4 stars overall and..."/>
Triple-S Management Corporation Awarded Four-Star Rating For Its HMO Offerings
Teleflex Incorporated announced today that financial results for the third quarter 2016 will be released before market open on Thursday, October 27, 2016. An investor conference call will be held at 8:00 a.m. on Thursday, October 27, 2016."/>
Teleflex Announces Third Quarter 2016 Earnings Conference Call Information
Anthem Medicare Membership Enrolled in Plans that Scored 4 Stars or Higher. INDIANAPOLIS---- Anthem Inc. has earned high Medicare Star Quality Ratings from the Centers for Medicare& Medicaid Services for its Medicare Advantage plans for 2017. In the most recent ratings released by CMS, nearly 51 percent of Anthem Medicare Advantage members will be enrolled in plans that achieved four stars or higher as compared with approximately 22 percent of members..."/>
Anthem Medicare Plans Score Significant Increases in 2017 Medicare Star Quality Ratings
BioTime, Inc., a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the Westin St. Francis Hotel in San Francisco."/>
BioTime to Present at the BIO Investor Forum

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology797 Articles
Consumer Discretionary705 Articles
Financials691 Articles
Industrials541 Articles
Health Care516 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at